Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus across all profitability metrics: revenue reached $183.9M (+2.2% vs. $179.9M expected), while normalized EPS of $0.91 outperformed the $0.61 estimate by 49.2%. Despite competitive pricing in Glucagon, the strong launch of Ipratropium Bromide and growth in high-margin products like Iron Sucrose expanded gross margins to 50.8% (vs. 49.1% expected). Management confirmed hitting the $175M annual sales milestone for BAQSIMI®, triggering a $100M payment to Eli Lilly in Q3.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Amphastar Pharma(AMPH) the Revenue is 183.9 M (+5.44%), Beat estimate;the EBIT is 53.09 M (-3.19%), Beat estimate;the EPS is 0.67 (+4.69%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.18B5.44%
0.18B3.16%
+0.00B2.28%
EBITExceed expectations
0.05B3.19%
0.04B25.00%
+0.01B21.81%
EPSExceed expectations
0.674.69%
0.3742.19%
+0.300046.88%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf